Member Info for researcher1

today announcing winding up and reforming into a new vehicle - the end must be in sight.....

good find Bermuda - I read this interview on a different platform. AN speaks in layman's terms, but it is still clear how impressive the Parsortix system is compared to all other available technologies...

we know it is down to Jupiter - they have already submitted a TR-1 showing what they have been up to.
by the way, you are also in considerably below recent purchases by directors...

Darren, you are in much lower than serious institutional investors and much much lower than recent US investors. You will be fine, and dandy.

spot on moon - but even if the SP was 80 at the moment, which it should be, it would still be a factor of 50 under its market potential - normally these shares are a factor of 50 (well 20 anyway) OVER their potential!

£80M Mcap as prospective leader in an annual £8B market. ha ha.

yes, I am cheesed off! I bought a load at 45 and 44 thinking I'd undercut the placees! Still, I now have a stack more at 40.5p and my average has never been as low....
As to the NHS initiative, I fear that is many, many years down the road (as I wrote yesterday) but if it works out, Angle will benefit, as more precise analyses will be required following the screening test.

if you are thinking of jumping in, you may like to watch out for a Holdings RNS by Jupiter - they are selling up as they are in trouble. Once they are out there's likely to be serious upward movement. It may take another week or so at current rates. Or just get in now.... bargain price for Black Friday!

hi Caterham - firstly, the NHS are part of a 3 year trial, which may eventually lead to Phase studies etc - so FDA is about 5 years down the line. Angle have made their submission already!
Then there is the quality of information - the NHS trial is a welcome move, but is broad spectrum, offering too much information, but useful as a start point. By contrast, Parsortix isolates and harvests live CTC cells that are cancer-specific, which can be tested to determine extent, virulence, treatment etc. So it would be like comparing an axe to a surgical knife, where precision (as opposed to logs) is the grail.
There could be a link up eventually maybe, with the Besos test revealing patients who are then tested more accurately using Parsortix.

thanks Dibs - me too, then I had to close a T20 and was offered 40.7

anyone bought or sold today ? I'm getting that price reversal effect again... can sell for more than I paid...
what the heck is going on? - I can only guess there are two parallel markets in operation, one for normal shares and one for Jupiter's?

confirmation bias, certainly! However, I broadly agree. No point in shouting from the rooftops, just buy quietly....

93.6 - so teetering into profit -just - today

not really - it's the million dollar (well, pound) question. They are in a hurry and have sold in excess of 18m shares, but the exact figure is hard to come by. Best guess - out before Xmas at latest.

this looks to be another of Winnifrith's dogs. I wonder how much they pay him to plug the share? I was in Fox when it was around 16p, but sold when Fiddly Tom got involved - thank goodness.

I think we've covered this one - only Jupiter are offloading (it is common knowledge they are in significant financial distress) and the other two have been diluted sufficiently to cross percentage thresholds.

hi Phantom - there's usually an anticipatory rise in the SP around a month before the earliest result date - so February, in normal circumstances - but AGL is well below 'par' value at present (which I'd say is around 57), so the question is, once Jupiter is out, will all the new holders just sit on their hands so the price rises, or will they start selling on 10 or 20% profits....

really? there has been consistent news flow compared to many. patience required. Anyway, I'm back in with £10K.

nice to be back in Ncyt profit again....

I have too - a fair chunk of my house sale. Thanks Jupiter.